[FOR RELEASE August 21, 2018 China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal BEIJING, China — August 21, 2018 — About China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutica]
[JOINT FILING AGREEMENT [Remainder of Page Intentionally Left Blank] GL Trade Investment Limited Hu Chou Hui Director GL China Opportunities Fund L.P. Zhenfu Li Authorized Signatory GL Capital Management GP L.P. Zhenfu Li Authorized Signatory GL Capital Management GP Limited Zhenfu Li Director GL Par]
[JOINT FILING AGREEMENT [Remainder of Page Intentionally Left Blank] GL Trade Investment Limited Hu Chou Hui Director GL China Opportunities Fund L.P. Zhenfu Li Authorized Signatory GL Capital Management GP L.P. Zhenfu Li Authorized Signatory GL Capital Management GP Limited Zhenfu Li Director GL Par]
[PROPOSAL LETTER August 17, 2018 The Board of Directors China Biologic Products Holdings, Inc. 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China Dear Members of the Board of Directors: Mr. Gao GL Capital BOCGI CDH Consortium ]
[FOR RELEASE August 13, 2018 China Biologic Names Bing Li as New CEO BEIJING, China — August 13, 2018 — Mr. David Hui Li, Chairman of China Biologic, stated, “I am very pleased that Dr. Li has agreed to take the position of Chief Executive Officer. I believe, with his extensive expertise in the pharm]
[FOR RELEASE August 13, 2018 China Biologic Names Bing Li as New CEO BEIJING, China — August 13, 2018 — Mr. David Hui Li, Chairman of China Biologic, stated, “I am very pleased that Dr. Li has agreed to take the position of Chief Executive Officer. I believe, with his extensive expertise in the pharm]
[FOR RELEASE August 3, 2018 China Biologic Reports Financial Results for the Second Quarter of 2018 --2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms— --]
[FOR RELEASE August 3, 2018 China Biologic Reports Financial Results for the Second Quarter of 2018 --2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms— --]
